Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus TOBRAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus TOBRAMYCIN SULFATE.
AMIKIN vs TOBRAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Adults: Tobramycin 3-5 mg/kg/day IV divided every 8 hours, or 5-7 mg/kg/day IV once daily. For inhalation: 300 mg nebulized twice daily.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 24-100 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Primarily renal (glomerular filtration) with 90-95% excreted unchanged in urine within 24 hours; biliary/fecal <1%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic